Asset Details
Do you wish to reserve the book?
Evolution of characteristics of MASLD with and without diabetes: a meta-analysis of placebo arms
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Evolution of characteristics of MASLD with and without diabetes: a meta-analysis of placebo arms
Do you wish to request the book?
Evolution of characteristics of MASLD with and without diabetes: a meta-analysis of placebo arms
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Evolution of characteristics of MASLD with and without diabetes: a meta-analysis of placebo arms
2024
Overview
Background
We explored the changes in metabolic dysfunction-associated steatotic liver disease (MASLD) severity over time by analyzing data from the placebo arms of randomized controlled trials (RCTs), focusing on the presence of diabetes.
Methods
RCTs on MASLD that included a placebo arm were identified using a systematic search of the literature. Primary outcomes were changes in hepatic steatosis and fibrosis.
Results
The meta-analysis included 8 RCTs involving 386 patients without diabetes and 24 RCTs involving 637 patients with diabetes. The pooled estimate of mean change in steatosis grade was − 0.1 in patients without diabetes, and − 0.37 in patients with diabetes (
P
= 0.066). The mean change in fibrosis stage was 0.05 in patients without diabetes, and − 0.03 in patients with diabetes (
P
= 0.359). The mean change in nonalcoholic fatty liver disease activity score was − 0.55 in patients without diabetes, and − 1.50 in patients with diabetes (
P
= 0.100). The mean change in ALT and AST were significantly larger in patients without diabetes compared to those with diabetes (
P
< 0.05).
Conclusion
Placebo treatment had a greater effect in improving liver steatosis in patients with diabetes compared to those without. These findings highlight the importance of tailored treatment strategies in MASLD, particularly considering diabetes status.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ Diabetes
/ Diabetes Mellitus - drug therapy
/ Fibrosis
/ Humanities and Social Sciences
/ Humans
/ Liver Cirrhosis - drug therapy
/ Metabolic dysfunction-associated steatotic liver disease
/ Non-alcoholic Fatty Liver Disease - drug therapy
/ Non-alcoholic Fatty Liver Disease - pathology
/ Placebos
/ Randomized Controlled Trials as Topic
/ Science
